Literature DB >> 30038946

Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice.

Swathi Ramakrishnan1, Wendy Huss1, Barbara Foster1, Joyce Ohm2, Jianmin Wang3, Gissou Azabdaftari4, Kevin H Eng3, Anna Woloszynska-Read1.   

Abstract

Cancer cells set in motion transcriptomic programs allowing for adaptation and growth in immunocompromised mice to form xenografts, a frequently used tool in cancer research. 2D cultures may not be representative of tumors growing in a complex host microenvironment. This can result in different responses to the same agent tested in vitro and in vivo which impedes the process of developing novel therapeutics. Understanding the transition cells undergo from 2D cell culture to a 3D host microenvironment will help in developing and choosing appropriate models for pre-clinical studies. Our study characterized the transcriptome of a three frequently used muscle-invasive bladder cancer cell lines HT1376, T24 and UM-UC-3 grown in culture and xenografts in nude mice. We found that bladder cancer cells undergo few transcriptomic changes when transitioned from 2D cell culture to xenografts in nude mice. UM-UC-3 cells have the least transcriptomic alterations followed by T24 and HT1376 cells. Respective xenografts cluster with their parental cell lines rather than other xenografts or cell lines. We applied established bladder cancer molecular subtypes to our data and found that UM-UC-3, containing the least transcriptomic alterations, most closely resembled the basal-like molecular subtype of bladder cancer. HT1376 and T24 have mixed basal and luminal molecular signatures. Our studies suggest this subset of bladder cancer cell lines and derived xenografts maintain similar transcriptomic profiles in both 2D culture and 3D xenografts and can be used interchangeably in pre-clinical studies.

Entities:  

Keywords:  2D cell culture; Bladder cancer; molecular subtypes; transcriptomics; xenografts

Year:  2018        PMID: 30038946      PMCID: PMC6055076     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  25 in total

1.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Authors:  Chantal Pauli; Benjamin D Hopkins; Davide Prandi; Reid Shaw; Tarcisio Fedrizzi; Andrea Sboner; Verena Sailer; Michael Augello; Loredana Puca; Rachele Rosati; Terra J McNary; Yelena Churakova; Cynthia Cheung; Joanna Triscott; David Pisapia; Rema Rao; Juan Miguel Mosquera; Brian Robinson; Bishoy M Faltas; Brooke E Emerling; Vijayakrishna K Gadi; Brady Bernard; Olivier Elemento; Himisha Beltran; Francesca Demichelis; Christopher J Kemp; Carla Grandori; Lewis C Cantley; Mark A Rubin
Journal:  Cancer Discov       Date:  2017-03-22       Impact factor: 39.397

Review 2.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

3.  A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Authors:  Janet Myungjin Lee; Paulette Mhawech-Fauceglia; Nathan Lee; Lucineh Cristina Parsanian; Yvonne Gail Lin; Simon Andrew Gayther; Kate Lawrenson
Journal:  Lab Invest       Date:  2013-03-04       Impact factor: 5.662

Review 4.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

Review 5.  Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies.

Authors:  Qianjun Zhou; John Facciponte; Min Jin; Qiang Shen; Qiang Lin
Journal:  Cancer Lett       Date:  2014-03-01       Impact factor: 8.679

6.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Authors:  Thomas Powles; Peter H O'Donnell; Christophe Massard; Hendrik-Tobias Arkenau; Terence W Friedlander; Christopher J Hoimes; Jae Lyun Lee; Michael Ong; Srikala S Sridhar; Nicholas J Vogelzang; Mayer N Fishman; Jingsong Zhang; Sandy Srinivas; Jigar Parikh; Joyce Antal; Xiaoping Jin; Ashok K Gupta; Yong Ben; Noah M Hahn
Journal:  JAMA Oncol       Date:  2017-09-14       Impact factor: 31.777

7.  Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

Authors:  M L Nickerson; N Witte; K M Im; S Turan; C Owens; K Misner; S X Tsang; Z Cai; S Wu; M Dean; J C Costello; D Theodorescu
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 8.  Intrinsic subtypes and bladder cancer metastasis.

Authors:  David J McConkey; Woonyoung Choi; Andrea Ochoa; Colin P N Dinney
Journal:  Asian J Urol       Date:  2016-09-23

9.  Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Authors:  Vipulkumar Dadhania; Miao Zhang; Li Zhang; Jolanta Bondaruk; Tadeusz Majewski; Arlene Siefker-Radtke; Charles C Guo; Colin Dinney; David E Cogdell; Shizhen Zhang; Sangkyou Lee; June G Lee; John N Weinstein; Keith Baggerly; David McConkey; Bogdan Czerniak
Journal:  EBioMedicine       Date:  2016-08-25       Impact factor: 8.143

10.  Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting.

Authors:  Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real
Journal:  Bladder Cancer       Date:  2016-01-07
View more
  4 in total

1.  Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment.

Authors:  Michalis Mastri; Swathi Ramakrishnan; Shruti D Shah; Ellen Karasik; Bryan M Gillard; Michael T Moser; Bailey K Farmer; Gissou Azabdaftari; Gurkamal S Chatta; Anna Woloszynska; Kevin H Eng; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2021-12-15

2.  Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.

Authors:  Amira Abugomaa; Mohamed Elbadawy; Megumi Yamanaka; Yuta Goto; Kimika Hayashi; Takashi Mori; Tsuyoshi Uchide; Daigo Azakami; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Risako Yamashita; Mio Kobayashi; Hideyuki Yamawaki; Yuta Shinohara; Masahiro Kaneda; Tatsuya Usui; Kazuaki Sasaki
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

3.  Intratumoral Heterogeneity Promotes Collective Cancer Invasion through NOTCH1 Variation.

Authors:  Peter Torab; Yue Yan; Mona Ahmed; Hironobu Yamashita; Joshua I Warrick; Jay D Raman; David J DeGraff; Pak Kin Wong
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

4.  GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells.

Authors:  Xiufei Gao; Zimei Yang; Chuchu Xu; Qinghong Yu; Mengqian Wang; Jiaqing Song; Chunyu Wu; Mingcang Chen
Journal:  Ann Transl Med       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.